GLP-1R, glucagon receptor (GCGR) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are validated therapeutic targets for type 2 diabetes and obesity11–13. Here, GIPR is linked to type 2 diabetes mellitus.